Stay one step ahead of modern health challenges
Preparing for tomorrow's world
By 2050, around 70% of the population is expected to be living in urban areas.1 We’re developing One-in-a-trillion bio-solutions to help protect the immune system from the impact of daily exposure to harmful compounds, pollution, and the spread of drug resistant pathogens.
We target key factors of modern living that can cause imbalances in the immune system
With over 55% of the world’s population living in urban areas, the constraints of urban living and a lack of space challenge our health.1 The spread of drug-resistant pathogens that lead to antimicrobial resistance is simultaneously continuing to make it more difficult to treat common infections.10
These circumstances can favor the spread of pathogens and can increase exposure to potentially harmful compounds, substances, and forms of pollution.1
Each of these factors can cause imbalances in the essential ways in which our bodies function - and can impact our well-being.
The number of global citizens living in these environments is set to grow to 68% by 2050, so it's vital we support our bodies and naturally protect them from these exposures.1
Consumer interest in preventative health is booming
Awareness around the benefits of a preventative approach to health is rising, as is consumer interest in natural solutions that help us maintain a healthy lifestyle.2 We dive deep into science and consumer insights related to immune health challenges and then combine data science and analytics to develop One-in-a-trillion bio-solutions.
Solutions for protective and immune health
OneHealth's first two products in the protective and immune category focus on two of the world's most widespread challenges.
Pylopass™
Reclaim "joie de vivre" with Pylopass, a postbiotic solution that may help reduce the load of H. pylori in the stomach.
SmartGuard™
A bright future starts lead free. SmartGuard™ is a safe and gentle probiotic developed to help limit daily lead absorption.
MenaquinGold™
Our natural vitamin K2 produced utilizing a patented chickpea fermentation process in our soy-free, non-GMO manufacturing facilities.
Stay in the loop with our newsletter
We respect your inbox, so we only send newsletters quarterly. Packed with our latest consumer insights, research and product innovations, we don't think you want to miss it. Sign-up here.
Related resources
Stress and the microbiota-gut-brain axis: a new frontier for stress management
Read more
Discover how we are innovating in each of these key consumer categories
References
https://www.who.int/health-topics/urban-health
Euromonitor International’s Voice of the Industry: COVID-19 Survey, April 2020, July 2020
World Gastroenterology Organisation, Global guidelines - Helicobacter pylori - May 2021: helicobacter-pylori-english-2021.pdf (worldgastroenterology.org)
World Health Organization, https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed
Hooi JKY et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology Volume 153, Issue 2, August 2017, Pages 420-429
Uspienskiy YP, Fomin YA, Ivanov SV, Menaker IO (2016). Evolution in eradication therapy of HP-associated diseases: beyond the standards? RMZ Med Obozrenie (197):1144-1152
Parolova NI, Kornienko EA, Antonov PV Egorov Mikhail Gorbunov EF, Dmitrienko MA. (2015). An Innovative Approach in the Treatment of H. pylori Infection in Children. RMJ, Vol 22
Kornienko EA, Parolova NI, Ivanov SV, Polev DS, Zykin PA, Kondratenko YD, Zakharchenko MM. Gastric microbiota and probiotics opportunities in helicobacter pylori eradication in children. Gastroenterol Hepatol Open Access. 2020;11(1):13-23.
Parth K, Prudhivi R, Palatheeya S, Abbas SK, Varsha K, Niharika BV, Lyngkhoi B. Efficacy of Lactobacillus reuteri Supplementation in Eradication of H. pylori: A Comparison Study with Triple Drug Therapy. Journal of Pharmaceutical Research International 33(52B): 151-159, 2021.
Antimicrobial resistance (who.int)